Cite
HARVARD Citation
Schrock, A. et al. (2021). RAS Amplification as a Negative Predictor of Benefit from Anti-EGFR–Containing Therapy Regimens in Metastatic Colorectal Cancer. Oncologist. pp. 469-475. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Schrock, A. et al. (2021). RAS Amplification as a Negative Predictor of Benefit from Anti-EGFR–Containing Therapy Regimens in Metastatic Colorectal Cancer. Oncologist. pp. 469-475. [Online].